STAT July 11, 2024
Good morning. We’ve got lots of news this morning, so let’s get straight into it.
Pfizer moves forward a daily GLP-1 obesity pill
Pfizer will advance a once-daily formulation of its oral GLP-1 obesity candidate, danuglipron, after facing multiple setbacks in the space.
The company said results from an ongoing pharmacokinetic study led it to choose a formulation to move forward, but did not provide details on the specific formulation. The company will still need to conduct dose optimization studies in the second half of this year.
Investors have been closely watching Pfizer’s work in obesity as the company faces pressure to find new growth generators amid declining sales of its Covid-19 products.
FTC to sue PBMs over...
Today's Sponsors
Today's Sponsor